LCD-DL40246
Document details
Summary
The proposed LCD for MolDX biomarker testing in DCIS could impact billing by establishing clear criteria for reimbursement, potentially increasing the number of eligible tests approved for coverage. TNew LCD could enhance coverage for DCIS biomarker tests.
Affected specialty
Oncology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=40245&ver=3CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA022437 · Oncology
Trelstar (triptorelin pamoate) is an intramuscular injectable GnRH agonist indicated for advanced prostate cancer, billing under Medicare Part B as a physician-administered drug. As an established inj
View alertPolicy FDA-NDA021288 · Oncology
Trelstar (triptorelin pamoate) is an intramuscular injectable approved for a new dosage form under NDA021288, placing it firmly in the Medicare Part B billing pathway as a physician-administered drug.
View alertPolicy FDA-NDA020715 · Oncology
Trelstar (triptorelin pamoate) is an intramuscular injectable indicated for prostate cancer, placing it squarely in the Medicare Part B billing pathway as a physician-administered drug. It is typicall
View alertPolicy FDA-NDA219304 · Oncology
Romvimza (vimseltinib) is an oral capsule kinase inhibitor approved via NDA219304, placing it squarely in the Medicare Part D billing pathway as a self-administered outpatient drug. As a new molecular
View alert